Philippe van Holle
Geen lopende functies
Oorsprong van het eerstegraads netwerk van Philippe van Holle
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands.
24
| Extinct | Miscellaneous Commercial Services | 24 |
| Extinct | Pharmaceuticals: Major | 12 | |
University of Antwerp
11
| College/University | Other Consumer Services | 11 |
Celgene International SARL
 Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the company is based in Boudry, Switzerland.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Philippe van Holle via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Sales & Marketing | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Academic Medical Center
 Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
Forbion Co-Investment II Coöperatief UA
 Forbion Co-Investment II Coöperatief UA Investment ManagersFinance Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch. | Investment Managers | Founder | |
| SWISS LIFE HOLDING AG | Life/Health Insurance | Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree Doctorate Degree | |
| CONCENTRA NV | Commercial Printing/Forms | President | |
| RETAIL ESTATES SA | Real Estate Investment Trusts | Chairman | |
| Imperial College London | College/University | Corporate Officer/Principal | |
Ageas NV
 Ageas NV Regional BanksFinance Ageas NV provides insurance and banking services. The firm offers retail, commercial, private and merchant banking and insurance services. The company provides financial services to companies, institutional clients, and individuals and provides integrated solutions to the enterprises and the entrepreneurs. It is headquartered in Utrecht, the Netherlands. | Regional Banks | Chief Executive Officer | |
BNP Paribas Fortis Private Equity Belgium NV
 BNP Paribas Fortis Private Equity Belgium NV Investment ManagersFinance BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels. | Investment Managers | Private Equity Investor | |
| University of Cambridge | College/University | Graduate Degree Undergraduate Degree | |
Krefima NV
 Krefima NV Regional BanksFinance Part of Bpost Banque SA, Krefima NV is a Belgian company that provides consumer credit. The company is based in Antwerp, Belgium. Krefima was acquired by bpost bank NV, a SUB of BNP Paribas SA from Z.B.G. Holdings NV on April 02, 2015. | Regional Banks | Chairman | |
| BNP PARIBAS FORTIS SA | Major Banks | Chief Operating Officer | |
| KBC GROUPE NV | Regional Banks | Director/Board Member Director/Board Member | |
| Moscow State University Lomonosov | College/University | Undergraduate Degree Doctorate Degree | |
| University of Amsterdam | College/University | Graduate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
| University of Leiden | College/University | Doctorate Degree | |
| University of Groningen | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| Vrije Universiteit Amsterdam | College/University | Undergraduate Degree | |
| Swiss Federal Institute of Technology | College/University | Corporate Officer/Principal Undergraduate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree Graduate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder | |
National Academy of Medicine (United States)
 National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Chairman | |
| Université Catholique de Louvain | College/University | Doctorate Degree Undergraduate Degree Masters Business Admin | |
Centea SA
 Centea SA Regional BanksFinance Centea SA provides banking services. | Regional Banks | Director/Board Member | |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| TINC N.V. | Investment Managers | Chairman Director/Board Member | |
| Groep T | College/University | Undergraduate Degree | |
SD Worx Sociaal Secretariaat VZW
 SD Worx Sociaal Secretariaat VZW Miscellaneous Commercial ServicesCommercial Services SD Worx Sociaal Secretariaat VZW engages in the provision of payroll, human resources and legal solutions. It offers staffing, compensation and benefits, training courses, consulting, and research services. The company was founded on October 22, 1946 and is headquartered in Antwerp, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Febelfin ASBL
 Febelfin ASBL Regional BanksFinance Febelfin ASBL provides banking services for refugees and asylum seekers. The firm fries to reconcile the interests of members with the policy makers, supervisors, trade associations and pressure groups. The company is headquartered in Bruxelles, Belgium. | Regional Banks | Chairman | |
| Voka Vlaams Economisch Verbond VZW | Director/Board Member Corporate Officer/Principal | ||
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Chief Executive Officer Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Director/Board Member Chairman Chief Executive Officer Founder Founder Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
| Stanford University School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
| Harvard Business School | College/University | Undergraduate Degree Masters Business Admin | |
| Rotterdam School of Management | College/University | Masters Business Admin Doctorate Degree | |
| BNP Paribas Fortis Foundation | Chairman | ||
| Oxyrane, Ltd. | Director/Board Member | ||
| HOOKIPA PHARMA INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
| LIQUIDIA CORPORATION | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman Founder |
Statistieken
Internationaal
| België | 17 |
| Verenigde Staten | 12 |
| Nederland | 11 |
| Verenigd Koninkrijk | 5 |
| Zwitserland | 3 |
Sectoraal
| Consumer Services | 16 |
| Finance | 14 |
| Health Technology | 13 |
| Commercial Services | 5 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 304 |
| Corporate Officer/Principal | 100 |
| Chairman | 65 |
| Independent Dir/Board Member | 62 |
| Chief Executive Officer | 41 |
Sterkste connecties
| Insiders | |
|---|---|
| Ralph Snyderman | 41 |
| Brian Underdown | 34 |
| Hugo Slootweg | 34 |
| Alan Colowick | 30 |
| Jean Lamarre | 29 |
| Steven Holtzman | 28 |
| Dirk Roger Goeminne | 27 |
| Ferdinand Verdonck | 25 |
| Joseph Feczko | 23 |
| Marc Descheemaecker | 20 |
| François Meyer | 20 |
| Filip Dierckx | 19 |
| Piers John Morgan | 18 |
| Sander J. van Deventer | 17 |
| George Morstyn | 17 |
- Beurs
- Insiders
- Philippe van Holle
- Bedrijfsconnecties